サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1765053

遺伝子治療の世界市場

Gene Therapy

出版日
ページ情報
英文 411 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円
遺伝子治療の世界市場
出版日: 2025年07月09日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 411 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

遺伝子治療の世界市場は2030年までに60億米ドルに達する見込み

2024年に17億米ドルと推定される遺伝子治療の世界市場は、2024年から2030年にかけてCAGR 23.0％で成長し、2030年には60億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるウイルス分野は、CAGR 23.3％を記録し、分析期間終了までに55億米ドルに達すると予測されます。非ウイルス性セグメントの成長率は、分析期間中CAGR 20.8％と推定されます。

米国市場は9億2,890万米ドルと推定、中国はCAGR29.5％で成長すると予測

米国の遺伝子治療市場は、2024年に9億2,890万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに2億1,630万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは29.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ20.1%と22.1%と予測されています。欧州では、ドイツがCAGR約22.0%で成長すると予測されています。

世界の遺伝子治療市場- 主要動向と促進要因まとめ

医療に革命を起こす遺伝子治療はどのように治療パラダイムを再定義しているのか？

遺伝子治療は、人の細胞内の遺伝物質を改変して病気を治療または予防する画期的な医療アプローチです。この革新的な治療法は、疾患開発の原因となる欠陥遺伝子を修正することにより、様々な疾患の治療法を提供できる可能性があります。遺伝子治療で使用される技術には、病気の原因となる変異遺伝子を健康なコピーと置き換えること、不適切に機能している変異遺伝子を不活性化すること、病気の治療に役立つ新しい遺伝子や改変遺伝子を体内に導入することなどが含まれます。これらの方法は主に、ヒトのDNAを運ぶように遺伝子改変されたウイルスであるベクターを通して行われます。遺伝子治療の可能性は、嚢胞性線維症や血友病のような遺伝性疾患の治療から、がん、心臓病、HIV/AIDSのようなより複雑な疾患にまで及ぶ。その開発は、従来の治療法からの大きな飛躍を意味し、1回の治療コースで長期的あるいは永続的な治療効果が期待できます。

限界への課題遺伝子治療を強化する次世代技術

技術の進歩は、遺伝子治療の精度と有効性を著しく向上させました。CRISPR-Cas9をはじめとする遺伝子編集技術の登場により、科学者たちはDNAを特定の位置で編集するかつてない精度のツールを手に入れ、突然変異をその発生源で修正できるようになりました。このような進歩は、治療を成功に導く可能性を高めるだけでなく、ゲノムの他の部分への意図しない影響など、旧来の遺伝子治療法に伴うリスクを軽減します。さらに、ベクター技術、特に非ウイルス性送達システムの開発における技術革新は、安全性と免疫反応管理に関するこれまでの課題を克服しつつあります。このような送達システムの強化により、治療用遺伝子がより効果的に標的細胞に到達し、意図したとおりに機能することが保証されます。

複雑性を克服する：現代の課題と倫理的ジレンマ遺伝子治療

その有望な可能性にもかかわらず、遺伝子治療は、臨床応用に影響するいくつかの課題と倫理的考察に直面しています。主な課題の1つは、遺伝子編集の長期的な影響がまだ十分に解明されていないため、長期的な安全性と有効性を確保することです。ゲノムの意図しない部分が編集され、予期せぬ結果につながるオフターゲット効果の可能性についても疑問が残ります。さらに、ウイルスベクターに対する免疫系の反応は、特にベクターとして使用されるウイルスに対する既存の免疫を持っている可能性のある患者にとっては、導入と効果を複雑にする可能性があります。倫理的な懸念もまた重要な役割を担っており、特に生殖細胞系列編集に関しては、遺伝子の変化が次世代に受け継がれる可能性があります。議論の中心は、人類の進化を変える可能性のある遺伝子改変を行うことの意味であり、治療法の開発と応用における厳格な倫理基準と規制の監視の必要性を強調しています。

医療革命の推進：拡大する遺伝子治療市場の主な促進要因

遺伝子治療市場の成長は、遺伝子研究やバイオテクノロジー技術の著しい進歩など、いくつかの要因によってもたらされています。遺伝性疾患の有病率の増加や、腫瘍学、神経学、希少疾患における新規治療に対するアンメットニーズの高さは、市場促進要因として大きいです。近年、いくつかの遺伝子治療薬が商業化に成功したことで、投資に対する大きなリターンの可能性が実証され、この分野の研究開発に多くの資金が集まるようになりました。さらに、希少疾病用医薬品の指定や早期承認などの規制上の優遇措置が、希少疾患や重篤な疾患に対する遺伝子治療の開発を後押ししています。消費者行動、特に個別化医療や持続的・永続的な治療法に対する需要の高まりも、市場を前進させています。さらに、バイオテクノロジー企業、製薬企業、学術機関の連携がイノベーションを促進し、研究から臨床への展開を加速させています。これらの要因は、世界のバイオ医薬品製造能力の向上と相まって、遺伝子治療ソリューションの継続的な成長と拡大を保証し、現代医学において最もダイナミックで変革的な分野の一つとなっています。

セグメント

ベクタータイプ（ウイルス性、非ウイルス性）;アプリケーション（がん疾患、希少疾患、心血管疾患、神経疾患、感染症、その他のアプリケーション）

調査対象企業の例

  • Amgen, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Bionomics Ltd.
  • BioMarin Pharmaceutical, Inc.
  • AnGes, Inc.
  • Amicus Therapeutics, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • bluebird bio, Inc.
  • Advantagene, Inc.
  • Biogen, Inc.
  • Abeona Therapeutics
  • Aptah
  • Avrobio
  • Arbor Biotechnologies, Inc.
  • Biocardia, Inc.

AIインテグレイションズ

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • ウイルスベクターが市場の大部分を占める
  • 非ウイルスベクターがより急速な成長を遂げる見込み
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP-1127

Global Gene Therapy Market to Reach US$6.0 Billion by 2030

The global market for Gene Therapy estimated at US$1.7 Billion in the year 2024, is expected to reach US$6.0 Billion by 2030, growing at a CAGR of 23.0% over the analysis period 2024-2030. Viral, one of the segments analyzed in the report, is expected to record a 23.3% CAGR and reach US$5.5 Billion by the end of the analysis period. Growth in the Non-Viral segment is estimated at 20.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$928.9 Million While China is Forecast to Grow at 29.5% CAGR

The Gene Therapy market in the U.S. is estimated at US$928.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$216.3 Million by the year 2030 trailing a CAGR of 29.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 20.1% and 22.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 22.0% CAGR.

Global Gene Therapy Market - Key Trends & Drivers Summarized

Revolutionizing Medicine: How Gene Therapy Is Redefining Treatment Paradigms?

Gene therapy represents a groundbreaking medical approach that involves modifying the genetic material within a person's cells to treat or prevent disease. This innovative therapy can potentially provide a cure for a range of disorders by correcting defective genes responsible for disease development. Techniques used in gene therapy include replacing a mutated gene that causes disease with a healthy copy, inactivating a mutated gene that is functioning improperly, or introducing a new or modified gene into the body to help treat a disease. These methods are primarily delivered through vectors, typically viruses that have been genetically altered to carry human DNA. The potential of gene therapy extends from treating hereditary diseases like cystic fibrosis and hemophilia to more complex conditions such as cancer, heart disease, and HIV/AIDS. Its development represents a significant leap from traditional treatments, offering hope for long-term or permanent therapeutic effects after a single treatment course.

Pushing the Boundaries: Next-Generation Techniques Enhancing Gene Therapy

Technological advancements have significantly improved the precision and efficacy of gene therapy. The advent of CRISPR-Cas9 and other gene-editing technologies has provided scientists with tools of unprecedented accuracy for editing DNA at specific locations, allowing for the correction of mutations at their source. These advancements not only increase the potential for successful treatment outcomes but also reduce the risks associated with older gene therapy methods, such as unintended effects on other parts of the genome. Additionally, innovations in vector technology, particularly in the development of non-viral delivery systems, are overcoming previous challenges related to safety and immune response management. These enhancements in delivery systems ensure that therapeutic genes reach the target cells more effectively and work as intended, which is critical for the treatment of diseases that require cellular-level interventions.

Navigating Complexities: The Challenges and Ethical Dilemmas of Modern Gene Therapy

Despite its promising potential, gene therapy faces several challenges and ethical considerations that influence its clinical application. One of the primary challenges is ensuring long-term safety and efficacy, as the long-term effects of gene editing are still not fully understood. Questions remain about the potential for off-target effects, where unintended parts of the genome may be edited, leading to unforeseen consequences. Additionally, the immune system's response to viral vectors can complicate delivery and effectiveness, particularly for patients who might have pre-existing immunity to the viruses used as vectors. Ethical concerns also play a significant role, particularly regarding germline editing, which could allow genetic changes to be passed down to future generations. The debate centers on the implications of making genetic modifications that could alter human evolution, underscoring the need for rigorous ethical standards and regulatory oversight in the development and application of gene therapy treatments.

Fueling a Medical Revolution: Key Drivers Behind the Expanding Gene Therapy Market

The growth in the gene therapy market is driven by several factors, including significant advancements in genetic research and biotechnological techniques. The increasing prevalence of genetic disorders and high unmet need for novel treatments in oncology, neurology, and rare diseases are major market drivers. The successful commercialization of several gene therapies in recent years has demonstrated the potential for substantial returns on investment, attracting more funding for research and development in this field. Additionally, regulatory incentives, such as orphan drug designations and accelerated approvals, encourage the development of gene therapies for rare and severe conditions. Consumer behavior, particularly the growing demand for personalized medicine and treatments that offer durable to permanent cures, also propels the market forward. Moreover, collaborations between biotech firms, pharmaceutical companies, and academic institutions are fostering innovation and speeding the translation of gene therapy from research to clinical settings. These factors, combined with the increasing global capacity for biopharmaceutical manufacturing, ensure continued growth and expansion of gene therapy solutions, making it one of the most dynamic and transformative fields in modern medicine.

SCOPE OF STUDY:

The report analyzes the Gene Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vector Type (Viral, Non-Viral); Application (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Other Applications)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 154 Featured) -

  • Amgen, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Bionomics Ltd.
  • BioMarin Pharmaceutical, Inc.
  • AnGes, Inc.
  • Amicus Therapeutics, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • bluebird bio, Inc.
  • Advantagene, Inc.
  • Biogen, Inc.
  • Abeona Therapeutics
  • Aptah
  • Avrobio
  • Arbor Biotechnologies, Inc.
  • Biocardia, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Gene Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • By Vector Type
  • VIRAL VECTORS ACCOUNT FOR A MAJOR SHARE OF THE MARKET
    • Adeno-Associated Virus Vectors
    • Lentivirus
  • NON-VIRAL VECTORS TO WITNESS FASTER GROWTH
    • US and Europe Dominate the Gene Therapy Market
    • Oncology Represents the Largest Indication for Gene Therapy
    • Market Outlook
    • Recent Market Activity
    • Select Innovations
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Availability of Novel Therapies Drive Market Growth
    • Select Approved Gene Therapy Products
    • Adeno-associated Virus Vectors - A Leading Platform for Gene Therapy
    • Lentiviral Vectors Witness Increasing Interest
    • Rising Cancer Incidence Worldwide Spurs Demand for Gene Therapy
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Compelling Level of Technology & Innovation to Ignite Gene Therapy
    • Promising Gene Therapy Innovations for Treatment of Inherited Retinal Diseases
    • Gene Therapy Pivots M&A Activity in Dynamic Domain of Genomic Medicine
    • M&As Rampant in Gene Therapy Space
    • Emphasis on Formulating Robust Regulatory Framework
    • Strong Gene Therapy Pipeline
    • Gene Therapy: Phase III Clinical Trials
    • OHSU Implements First-Ever LCA10 Gene Therapy Clinical Trial with CRISPR
    • Growing Funding for Gene Therapy Research
    • Market Issues & Challenges
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 3: World 13-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2017, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 6: World 13-Year Perspective for Viral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Non-Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Non-Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 9: World 13-Year Perspective for Non-Viral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Oncological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Oncological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 12: World 13-Year Perspective for Oncological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Rare Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Rare Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 15: World 13-Year Perspective for Rare Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 18: World 13-Year Perspective for Neurological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 21: World 13-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2025 & 2030
    • TABLE 22: World Gene Therapy Market Analysis of Annual Sales in US$ Thousand for Years 2017 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 25: USA 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 28: USA 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 31: Canada 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 34: Canada 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030
  • JAPAN
    • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 37: Japan 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 40: Japan 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030
  • CHINA
    • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 43: China 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 46: China 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030
  • EUROPE
    • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Gene Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Gene Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 49: Europe 13-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2017, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 52: Europe 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 55: Europe 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030
  • FRANCE
    • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 58: France 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 61: France 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030
  • GERMANY
    • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 64: Germany 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 67: Germany 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 70: Italy 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 73: Italy 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030
  • UNITED KINGDOM
    • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 76: UK 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 79: UK 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 82: Rest of Europe 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 85: Rest of Europe 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030
  • ASIA-PACIFIC
    • Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 88: Asia-Pacific 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 91: Asia-Pacific 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 94: Rest of World 13-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2025 & 2030
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2023 and % CAGR
    • TABLE 97: Rest of World 13-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2025 & 2030

IV. COMPETITION